Expression of poly(Adenosine Diphosphate-Ribose) polymerase protein in breast cancer [PDF]
Background: The use of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors for breast cancer (BC) therapy is the subject of debate, and there is an urgent need to understand much the expression and prognostic role of the PARP1 protein.
Akanksha +6 more
doaj +5 more sources
Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer. [PDF]
Pancreatic cancer is the third most common cause of cancer death in the United States and eleventh worldwide. The majority of patients present with advanced disease with five-year overall survival of less than 10%. Traditional chemotherapy has been the mainstay treatment for years, with limited improvement in survival.
Sunkara T +5 more
europepmc +5 more sources
Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy [PDF]
Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control.
Thomas Helleday, Cecilia E. Ström
doaj +4 more sources
Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis. [PDF]
BACKGROUND:Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic
Weiqiang Qiao +4 more
doaj +3 more sources
Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer. [PDF]
Visual Abstract The poly-(adenosine diphosphate-ribose) polymerase (PARP) family of proteins participates in numerous functions, most notably the DNA damage response.
Young AJ +14 more
europepmc +4 more sources
BackgroundPredicting serious hematological adverse events (SHAEs) from poly (adenosine diphosphate ribose) polymerase inhibitors (PARPis) would allow us to prioritize patients with ovarian cancer at higher risk for more intensive ...
Xiaotong Lian, Yu Lei
doaj +3 more sources
Poly–adenosine diphosphate–ribose polymerase inhibition for myocardial protection: Pathophysiologic and physiologic considerations [PDF]
Plantilles de l’Institut Barcelona Esports, de l’Institut Municipal del Paisatge Urbà i la Qualitat de Vida, de l’Institut Municipal d'Informàtica, de l’Institut Municipal d'Hisenda, de l’Institut Municipal d'Educació, de l’Institut Municipal de Mercats,
Wilhelm Bloch, Uwe Mehlhorn
openalex +3 more sources
Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. [PDF]
Recently, the development of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under
Park SR, Chen A.
europepmc +4 more sources
Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. [PDF]
The chromatin-bound enzyme poly(ADP-ribose) polymerase (ADPRP) is strongly stimulated by DNA with single- or double-stranded breaks, and transfers the ADP-ribose moiety of NAD to nuclear proteins. The activation of ADPRP is important for DNA repair and replication, and also has been postulated to play a role in the pathogenesis of lymphocyte ...
Hisashi Yamanaka +5 more
openalex +3 more sources
Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview [PDF]
In Latin America, prostate cancer is the third most common cancer overall and the most common in men, with the highest mortality rate of all cancers.
Rodolfo Borges dos Reis MD, PHD +9 more
doaj +2 more sources

